Dr. Eric Donnenfeld uses single-dose postoperative steroid — 4 insights

Written by Eric Oliver | March 15, 2019 | Print  |

Garden City, N.Y.-based Ophthalmic Consultants of Long Island's Eric Donnenfeld, MD, used EyePoint Pharmaceutical's single-dose postoperative steroid Dexycu in a cataract surgery patient.

What you should know:

1. Dexycu is an FDA-approved postoperative steroid designed to simplify the recovery process. Dexycu is single-dose steroid administered at the end of surgery that eliminates the need for a postoperative dosing regimen.

2. Dr. Donnenfeld performed the cataract surgery at Westbury, N.Y.-based Island Eye Surgicenter using Dexycu at its completion.

3. EyePoint is launching Dexycu through a phased rollout, starting with experienced cataract surgeons.

4. EyePoint will make Dexycu available to patients in need of financial assistance through its EyePoint Assist program.

More articles on leadership:
4 ways to reduce SSIs in ASCs
How to proactively tackle physician burnout: Acadia Healthcare CMO Dr. Michael Genovese weighs in
Arizona Medicaid program alerts 3,146 members of privacy breach: 3 details to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.